Samsung showcases enhanced portfolio at RSNA 2024

SEOUL, Korea – December 2, 2024 – Samsung Electronics Medical Device Division and Samsung Medison participated in Radiological Society of North America (RSNA) 2024 in Chicago Dec. 1-5 (local time), showcasing an even more diverse product lineup. 

At this exhibition, Samsung launched a new ‘floor-mounted’ digital X-ray, GF 85. The new digital X-ray, GF 85 launched by Samsung after two years is relatively affordable compared to ceiling-mounted type and cost-effective with the ability to be installed in a small space without ceiling construction. Moreover, it provides clear image quality even with low dose and is equipped with advanced AI diagnostic assistance feature, fully inheriting all the advantages of previous digital X-ray models. 

All products of Samsung digital X-ray are certified by FDA as "low dose," making it more appropriate for the diagnosis of children and adolescents where safety is particularly prioritized. Samsung's proprietary S-Vue imaging engine reduces radiation exposure by up to 50% compared to systems without this technology. 

To strengthen its competitiveness across medical specialties, after the launch of a new OB & GYN ultrasound diagnostic system, HERA Z20, Samsung proposed "pediatric integrated solution" encompassing the entire range of its medical diagnostic devices through this RSNA. 

In the ‘Ultrasound Zone,’ a dedicated probe for the pediatric cardiac diagnosis ‘TA2-9’ was unveiled for the first time at this exhibition. The TA2-9 with 42% smaller head than adult echocardiography probe aids in more accurate diagnosis for congenital heart disease or functional and structural abnormalities of heart through the oral route. Also, on display was ‘L3-22’, a dedicated neonatal probe featuring a smaller head compared to an adult version offering a wide frequency range which enables pediatric body scan with a single device without the need to switch probes. 

Samsung includes OmniTom Elite in its portfolio, the mobile CT useful for imaging pediatric patients with difficulty moving. The system is already recognized for its utility, with eight out of the top 10 U.S. children's hospitals (as ranked by U.S. News for 2024-2025) utilizing Samsung's portable CT devices. 

The OmniTom Elite PCD displayed at RSNA 2024 provides CT imaging with high resolution and low noises using FDA-approved PCD technology compared to conventional CT methods using scintillators. Leveraging PCD technology, Samsung plans to further reduce radiation doses and release an upgraded version of the OmniTom Elite PCD in 2025 that enables full-body imaging for pediatric patients. 

Samsung provides opportunity to gain clinical application tips of Samsung medical devices and engage in a Q&A with the global experts through Lunch & Learn session. In this session, a global breast imaging expert, Dr. Nina Vincoff, shared a screening program using Samsung breast ultrasound solution, and the latest insights on the FDA’s mandate for breast density information provision and implementation of additional imaging examination recommendation for dense breast (effective on Sept. 10, 2024). 

Dr. Farhad Farzanegan in Kaiser Permanente South Sacramento health system U.S. presented a case study on hospital workflow improvement based on the result of CT intervention procedure using Samsung's mobile full-body CT, BodyTom. 

In the booth, Dr. Jon Jacobson, a musculoskeletal radiology expert, conducted live scans using a premium ultrasound diagnostic device, RS85 Prestige introducing clearer image quality and more sophisticated AI diagnostic assistance feature. 

The leader of the Samsung Medison AI Informatics group, Vijay, said “I discovered a greater potential through high praises from medical professors around the world who visited the site." 

"Moving forward, we aim to further enhance our AI diagnostic support features tailored to specialized medical fields, solidify our technological leadership in radiology and obstetrics, and expand our competitiveness across all medical disciplines to pioneer new markets," Vijay added.